Platelet Activating Factor

Platelet Activating Factor

SCHEMBL433361

CCCCCCCCCCCCCCCCOC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(C)=O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRA1D P25100 1/20 1.00
PTAFR P25105 1/20 1.00
HTR1D P28221 1/20 1.00
HTR2C P28335 1/20 1.00
ADRA1B P35368 1/20 1.00
DRD3 P35462 1/20 1.00
TMEM97 Q5BJF2 1/20 1.00
MAPT P10636 1/20 0.77
ALDH1A1 P00352 2/20 0.76
SMN1; SMN2 Q16637 2/20 0.76
PRKD3 O94806 1/20 0.76
PRKCG P05129 1/20 0.76
PRKCB P05771 1/20 0.76
PRKCA P17252 1/20 0.76
PRKCH P24723 1/20 0.76
AKT1 P31749 1/20 0.76
PRKCI P41743 1/20 0.76
PRKCE Q02156 1/20 0.76
PRKCQ Q04759 1/20 0.76
PRKCZ Q05513 1/20 0.76

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30655807 1.00 ADRA1D (1.00) ADRA1DPTAFRHTR1DHTR2CADRA1B
SCHEMBL30652762 1.00 ADRA1D (1.00) ADRA1DPTAFRHTR1DHTR2CADRA1B
SCHEMBL30652521 1.00 ADRA1D (1.00) ADRA1DPTAFRHTR1DHTR2CADRA1B
SCHEMBL34464893 1.00 ADRA1D (1.00) ADRA1DPTAFRHTR1DHTR2CADRA1B
SCHEMBL435191 1.00 ADRA1D (1.00) ADRA1DPTAFRHTR1DHTR2CADRA1B
Platelet Activating Factor SCHEMBL2734461 1.00 ADRA1D (1.00) ADRA1DPTAFRHTR1DHTR2CADRA1B
SCHEMBL2534238 1.00 ADRA1D (1.00) ADRA1DPTAFRHTR1DHTR2CADRA1B
SCHEMBL30366852 1.00 ADRA1D (1.00) ADRA1DPTAFRHTR1DHTR2CADRA1B
SCHEMBL30650457 1.00 ADRA1D (1.00) ADRA1DPTAFRHTR1DHTR2CADRA1B
Platelet Activating Factor SCHEMBL1392735 1.00 ADRA1D (1.00) ADRA1DPTAFRHTR1DHTR2CADRA1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 2781 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4434588-B1 AEROSOL DELIVERY DEVICE PARI PHARMA GMBH (DE) 2026-04-08 EP claimed
EP-3551388-B1 ABRASIVE ARTICLE AND METHOD OF GRINDING 3M INNOVATIVE PROPERTIES COMPANY (US) 2026-01-28 EP claimed
EP-4684213-A1 METHODS FOR ASSESSING PLATELET FUNCTION University of Reading (GB) 2026-01-28 EP claimed
US-20250295730-A1 METHODS AND MATERIALS FOR MODULATING T CELL ACTIVATION USING TRAILshort POLYPEPTIDES MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH 2025-09-25 US claimed
US-20250275951-A1 DRUGS TARGETING INFLAMMATION FOR THE TREATMENT OF OSTEOARTHRITIS AND OTHER INFLAMMATORY DISEASES THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS 2025-09-04 US claimed
US-12371438-B2 Ginkgolide B derivative and salt thereof, preparation method therefor and use thereof Huiling Jinxin (Shanghai) Pharmaceutical Technology Co., Ltd (CN) 2025-07-29 US claimed
US-20250222189-A1 Blood And Toxin Filter Device And Use Of Same CYTOSORBENTS CORPORATION 2025-07-10 US claimed
US-12352759-B2 Assay method of antibody KASHIV BIOSCIENCES, LLC (US) 2025-07-08 US claimed
WO-2025137591-A1 COMPOSITIONS, METHODS, AND SYSTEMS FOR PROMOTING ZINC SOLUBILIZATION AND ZINC UPTAKE IN PLANTS Tenfold Technologies, LLC (US) 2025-06-26 WO claimed
US-20250195684-A1 DELIVERY METHODS USING PLATELETS CHILDREN'S HOSPITAL MEDICAL CENTER (US) 2025-06-19 US claimed
US-20220093221-A1 SYSTEM FOR ASSESSING DRUG EFFICACY AND RESPONSE OF A PATIENT TO THERAPY THE S.M.A.R.T. CORPORATION 2022-03-24 US claimed
EP-3964514-A1 GINKGOLIDE B DERIVATIVE AND SALT THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF Huiling Jinxin (Shanghai) Pharmaceutical Technology Co., Ltd (CN) 2022-03-09 EP claimed
WO-2022047234-A1 DRUG COMBINATION KITS AND METHODS OF DRUG DELIVERY PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2022-03-03 WO claimed
CN-114002421-A Application of exosome metabolite as bipolar affective disorder marker 佛山市第三人民医院(佛山市精神卫生中心) 2022-02-01 CN claimed
US-7973023-B2 Oxidized lipids and uses thereof in the treatment of inflammatory diseases and disorders VASCULAR BIOGENICS LTD. (IL) 2011-07-05 US claimed
US-7902176-B2 Etherified oxidized phospholipids for inducing tolerance to oxidized LDL via mucosal administration; 1-hexadecyl-2-(5'-oxo-pentanyl)-sn-glycero-3-phosphocholine (D-ALLE) VASCULAR BIOGENICS LTD. (IL) 2011-03-08 US claimed
US-20100048515-A1 Oxidized lipids and uses thereof in the treatment of inflammatory diseases and disorders VASCULAR BIOGENICS LTD. (IL) 2010-02-25 US claimed
US-20080261865-A1 Oxidized Lipids and Uses Thereof in the Treatment of Inflammatory Diseases and Disorders VASCULAR BIOGENICS LTD. (IL) 2008-10-23 US claimed
US-20070099868-A1 Oxidized lipids and uses thereof in the treatment of inflammatory diseases and disorders VASCULAR BIOGENICS LTD. (IL) 2007-05-03 US claimed
EP-0638646-B1 Oxidized phospholipid degrading enzyme and gene thereof SUNTORY LTD (JP) 2001-12-19 EP claimed